Form 4: Nuvalent CSO Exercises Options, Sells Shares Under 10b5-1 Plan

Nuvalent's Chief Scientific Officer, Henry E. Pelish, executed pre-planned stock option exercises and subsequent sales of Class A Common Stock.

Summary

• Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc. (NUVL), reported transactions involving the company's Class A Common Stock.
• Transactions occurred on March 12, 2026, and March 13, 2026, under a Rule 10b5-1 trading plan adopted on December 11, 2025.
• Pelish acquired a total of 17,320 shares through the exercise of stock options at prices ranging from $18.93 to $72.35 per share.
• Concurrently, Pelish disposed of a total of 35,104 shares of Class A Common Stock through sales at weighted average prices ranging from $97.79 to $99.71 per share.
• Following these transactions, Pelish's direct beneficial ownership of Class A Common Stock stands at 65,604 shares.
• The stock options exercised had various vesting schedules, with some fully vested and others vesting over four years from their respective grant dates.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there is insider selling, it was pre-planned under a 10b5-1 plan, mitigating concerns of opportunistic trading, and the executive realized significant gains from option exercises.

Positives

• The Chief Scientific Officer realized significant gains by exercising stock options at substantially lower prices ($18.93 $72.35) compared to the sale prices ($97.79 $99.71).
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to personal financial management rather than opportunistic selling.

Negatives

• The net disposition of 17,784 shares (35,104 sold 17,320 acquired) by a key executive could be perceived by some investors as a reduction in insider exposure, although it is a common liquidity event.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales executed under a Rule 10b5-1 plan, are a routine aspect of executive compensation and personal financial planning within the biotechnology and pharmaceutical industries. Such plans allow insiders to sell shares at pre-determined times or prices to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders may observe the reduction in direct insider ownership, but the pre-planned nature of the sales under a 10b5-1 plan suggests these transactions are for personal liquidity and compensation rather than a reflection of new company-specific information.

Key Dates

Keywords

Nuvalent, NUVL, Insider Trading, Form 4, Stock Options, Share Sale, Henry E. Pelish, Chief Scientific Officer, 10b5-1 Plan